Valued at nearly US$ 25 billion, the market for benign prostatic hyperplasia prostate treatments is expected to grow at a steady growth rate of nearly 5 per cent through the end of 2028. This can be largely attributed to the increased population of elderly males, and associated health conditions for years ahead. Health risks associated with surgical options and growing needs for improvements in existing treatment options are anticipated to remain an upward trend in the near future.

Growing Awareness about Health and Treatments for Urological Disorders Increases Demand

The rising number of incidences of benign prostatic hyperplasia, increasing population of geriatrics and easy availability of information regarding treatments for urological ailments and prostate diseases are major influencers that will drive the growth of the global benign prostatic hyperplasia treatment market.

Consequently, minimally-, or non-invasive surgical procedures are expected to outpace the adoption of therapeutics and drugs, while creating more opportunities for health care providers in the near future. In addition, lucrative market potential from developing countries, and rapid innovation of new treatment products are projected to bode well for manufacturers in the years ahead.

Novel Treatment Techniques for Benign Prostatic Hyperplasia Allows for More Efficient Management

The FMI report projected a strong growth for benign prostatic hyperplasia prostate treatments. At present extensive clinical trials are being conducted on the development of innovative treatment techniques.

On the basis of surgical procedures, the prostatic urethral lifts are widely considered as an efficient treatment method for benign prostatic hyperplasia. However, in terms of drugs and therapeutics, alpha blockers are highly preferred by health care professionals, either as oral medications or direct injections to the prostate region.

High Costs of Treatments Restrict Adoption of Benign Prostatic Hyperplasia Treatments

Prohibitive Costs of healthcare related to the prescriptions for benign prostatic hyperplasia is a major challenge for stakeholders in the market. This can be attributed to the high complexity and severity of the condition that may require a wide variety of drugs in combination with various surgical options, which can cause great fluctuations in the expenses required.

Minimally invasive surgeries are relatively cheaper to open surgeries, and also pose lesser risk in terms of organ damage and further ailments when combined with drug therapy. The rising costs of benign prostatic hyperplasia treatment are directly affected by higher numbers of geriatric patients, which will positively influence the market for the near future.

Download free sample copy of this report with table of content and figures:

Published by Sandali

A former journalist, Sandali is a content marketer with over 5 years of writing experience, across various industries including Food Innovation, Healthcare, and IoT and Technology. Sandali has been weaving corporate stories for organizations through different forms of impactful marketing content. Her key aim is to strategically align well-crafted narratives with business objectives, translating into a powerful communications platform for the company.

Leave a comment

Your email address will not be published. Required fields are marked *